Results 81 to 90 of about 84,234 (301)
European Neuropsychopharmacology, 2019 Background: Olanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction.
J. Cunningham +6 more
semanticscholar +1 more source
Olanzapine Overdose in a Pin Point Pupil with Altered Sensorium [PDF]
Asia Pacific Journal of Medical Toxicology, 2017 Background:Olanzapine is a highly tolerable and easily affordable atypical antipsychotic drug which has been commonly prescribed in both inpatient and outpatient settings for several mental disorders.
Naresh Midha +3 more
doaj +1 more source
Symptomatic treatment of children with anti-NMDAR encephalitis. [PDF]
, 2016 AIM: We performed the first study on the perceived benefit and adverse effects of symptomatic management in children with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis.
Brilot, F +7 more
core +1 more source
Molecular imprinting for neurology: Materials, applications, and limitations
Ibrain, EarlyView.Molecularly imprinted materials: diagnostic, therapeutic and research applications in neurology. Molecularly imprinted materials offer high specificity and affinity for target molecules in neurological applications. This review highlights their synthesis, characterisation, and use in diagnostics, research and therapeutics.
Xiaohan Ma +3 more
wiley +1 more source
Macromolecular Rapid Communications, EarlyView.Mono‐ and bivalent‐, alanine‐modified poly‐iso‐butylenes, folding into beta‐sheets, were prepared by living carbocationic polymerization and subsequent endgroup modification. These PIB‐conjugates are useful as solid polymers for the drug release of triamcinolone and nimodipine. ABSTRACT Poly‐iso‐butylene (PIB) is a well known biocompatible polymer with
Philipp S. Hilgeroth +2 more
wiley +1 more source
Effect of metformin on olanzapine-induced weight gain: A 12-week randomised open-label study
Journal of Clinical SciencesBackground: Olanzapine is an atypical antipsychotic used in schizophrenia and bipolar affective disorder, but it is associated with weight gain and metabolic syndrome.
G. Chetan Kumar +3 more
doaj +1 more source
Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey [PDF]
, 2015 Background Clozapine is widely prescribed and, although effective, can cause weight gain and dysglycemia. The dysmetabolic effects of clozapine are thought to be more prevalent in women with this gender on average attaining 17 % higher plasma clozapine ...
Anderson, Simon G. +7 more
core +2 more sources
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.
Cochrane Database of Systematic Reviews, 2017 BACKGROUND Olanzapine as an antiemetic represents a new use of an antipsychotic drug. People with cancer may experience nausea and vomiting whilst receiving chemotherapy or radiotherapy, or whilst in the palliative phase of illness.
A. Sutherland +6 more
semanticscholar +1 more source
Cellular Physiology and Biochemistry, 2018 Background/Aims: Olanzapine, an atypical antipsychotic drug, has therapeutic effects for schizophrenia. However, clinical reports indicate that patients taking atypical antipsychotic drugs are at high risk of metabolic syndrome with unclear mechanisms ...
Chia-Hui Chen +3 more
semanticscholar +1 more source
Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review
Movement Disorders Clinical Practice, EarlyView.Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source